CTLA4 and metastatic melanoma: A 27-year-old man with metastatic melanoma treated with the combination of an anti-CTLA-4 and an anti-PD1 agent developed steroid-refractory ir-hepatitis and was treated with one cycle of infliximab at the standard dose of 5 mg/kg, achieving the normalization of transaminases.